Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura by Oh, J. et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0)
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
BLOOD RESEARCH VOLUME 54ㆍNUMBER 3September 2019 ORIGINALARTICLE
Prognostic utility of ADAMTS13 activity for the atypical hemolytic 
uremic syndrome (aHUS) and comparison of complement serology 
between aHUS and thrombotic thrombocytopenic purpura
Jisu Oh1, Doyeun Oh1, Seon Ju Lee2, Jeong Oh Kim2, Nam Keun Kim2, So Young Chong1, Ji Young Huh3, 
Ross I. Baker4, on behalf of the Korean TTP Registry Investigators
1Department of Internal Medicine, CHA Bundang Medical Center, CHA University, 2Institute for Clinical Research, School of 
Medicine CHA University, 3Department Laboratory Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea, 
4Western Australian Centre for Thrombosis and Haemostasis, Murdoch University, Perth, Australia
p-ISSN 2287-979X / e-ISSN 2288-0011
https://doi.org/10.5045/br.2019.54.3.218
Blood Res 2019;54:218-228.
Received on June 10, 2019
Revised on August 9, 2019
Accepted on August 12, 2019
Background
Atypical hemolytic uremic syndrome (aHUS) involves dysregulation of the complement 
system, but whether this also occurs in thrombotic thrombocytopenic purpura (TTP) re-
mains unclear. Although these conditions are difficult to differentiate clinically, TTP can 
be distinguished by low (＜10%) ADAMTS13 activity. The aim was to identify the differ-
ences in complement activation products between TTP and aHUS and investigate 
ADAMTS13 activity as a prognostic factor in aHUS.
Methods
We analyzed patients with thrombotic microangiopathy diagnosed as TTP (N=48) or 
aHUS (N=50), selected from a Korean registry (N=551). Complement activation prod-
ucts in the plasma samples collected from the patients prior to treatment and in 40 healthy 
controls were measured by ELISA.
Results
The levels of generalized (C3a), alternate (factor Bb), and terminal (C5a and C5b-9) mark-
ers were significantly higher (all P＜0.01) in the patients than in the healthy controls. 
Only the factor Bb levels significantly differed (P=0.008) between the two disease 
groups. In aHUS patients, high normal ADAMTS13 activity (≥77%) was associated with 
improved treatment response (OR, 6.769; 95% CI, 1.605‒28.542; P=0.005), remission 
(OR, 6.000; 95% CI, 1.693‒21.262; P=0.004), exacerbation (OR, 0.242; 95% CI, 0.064‒
0.916; P=0.031), and disease-associated mortality rates (OR, 0.155; 95% CI, 0.029‒
0.813; P=0.017).
Conclusion
These data suggest that complement biomarkers, except factor Bb, are similarly activated 
in TTP and aHUS patients, and ADAMTS13 activity can predict the treatment response 
and outcome in aHUS patients.
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INTRODUCTION
Thrombotic microangiopathies (TMAs) are occlusive mi-
cro/macrovascular diseases that often present with intra-
luminal thrombus formation. TMAs are also clinically de-
scribed as microangiopathic hemolytic anemia and thrombo-
cytopenia, for which the main forms are thrombotic throm-
bocytopenic purpura (TTP) and atypical hemolytic uremic 
syndrome (aHUS) [1, 2]. TTP is a hematological disorder 
with renal or neurological involvement and platelet-rich 
thrombi in small vessels [1]. The major pathogenesis of TTP 
involves deficient ADAMTS13 (a disintegrin and metalloprotease 
with a thrombospondin type 1 motif, member 13) activity 
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Fig. 1. CONSORT diagram of the 
patients included in analysis.
Abbreviations: ADAMTS13, a dis-
integrin and metalloproteinase with 
a thrombospondin type 1 motif, 
member 13; aHUS, atypical hemolytic 
uremic syndrome; PEX, plasma 
exchange; STEC-HUS, Shiga-like 
toxin-producing E. coli hemolytic 
uremic syndrome; TMA, thrombotic 
microangiopathy; TTP, thrombotic 
thrombocytopenic purpura. 
resulting from either a genetic abnormality or the presence 
of inhibitory antibodies [2]. A deficiency of ADAMTS13 
activity results in the accumulation of ultra-large multimers 
of von Willebrand factor (VWF) due to the loss of cleavage 
of the 842Tyr-843Met peptide bonds in the A2 domain [3], 
causing adhesion of the platelets to vascular walls. By con-
trast, aHUS results from hyperactivity of the alternative com-
plement pathway due to gene mutations producing a loss 
of regulatory function [i.e. CFH, CFI, CD46 (MCP), or THBD] 
or a gain of effector function (CFB or C3) [1, 4-6]. A loss 
of regulation that results in unrestricted complement activa-
tion leads to endothelial perturbation, leukocyte recruitment, 
platelet activation, tissue damage, and thrombus formation, 
eventually leading to end-organ failure [7]. Although the 
clinical features of TTP and aHUS overlap, neurological man-
ifestations are more prevalent in TTP, whereas aHUS typi-
cally has more severe renal involvement. Despite improve-
ments in clinical and research-based approaches, few reliable 
markers that predict patient outcome have been identified.
This study examined whether complement activation 
products can be used as biomarkers to differentiate aHUS 
from TTP and whether they can predict the response to 
plasma exchange (PEX) treatment and the prognosis, early 
in the course of therapy. We focused on how complement 
biomarkers or ADAMTS13 activity are related to the prog-
nosis and clinical outcomes of the patients treated for aHUS. 
MATERIALS AND METHODS
Patients
Since 2005, the hematology-oncology laboratory at CHA 
Bundang Medical Center has been the only nationwide re-
ferral center in Korea in charge of ADAMTS13 activity analy-
sis and the collection of data from teaching hospitals for 
the Korean TTP & TMA registry [8]. Among the 551 patients 
enrolled in the registry between February 2012 and 
December 2015, data from those diagnosed with TTP and 
aHUS were retrospectively analyzed (Fig. 1). Patients with 
ADAMTS13 activity of ＜10% (N=48) were selected as the 
TTP group. Of the remaining 503 patients, 50 Korean patients 
＞18 years of age met the diagnostic criteria of aHUS or 
were identified by genetic testing (N=9). The diagnoses were 
confirmed by the central laboratory physician (DO) after 
reviewing the clinical information and by the referring physi-
cians contacted by telephone or e-mail. No patient was treat-
ed with Eculizumab (anti-C5 monoclonal antibody) because 
it was not approved for the treatment of aHUS in Korea 
during the study period. Control samples were collected 
from 40 voluntary healthy donors. The study was in accord-
ance with the Declaration of Helsinki and was approved 
by the Institutional Review Board of CHA Bundang Medical 
Center; all the patients provided written informed consent.
Evaluation and measurements
Clinical information and blood samples were collected 
at admission (i.e., the first day TTP or aHUS was suspected 
and before treatment). The collected samples were sent to 
a central laboratory (CHA Bundang Medical Center, CHA 
University) for SDS-agarose gel electrophoresis determi-
nation of ADAMTS13 activity via VWF degradation [8]. 
Samples prospectively collected before administration of any 
intervention were spun down within 30 min (1,500×g for 
20 min at room temperature) to obtain aliquots of plate-
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Age (yr)      55 (24–72)          52 (21–87)          51 (12–81)          53 (23–88) 0.876 
Female (%)   50.0 (20/40)       64.6 (31/48)       41.5 (17/41)       22.2 (2/9) 0.124 
Symptoms 
   Fever (%) -       50.0 (24/48)       56.1 (23/41)       55.6 (5/9) 0.837 
   Severe neurological 
symptoms (%)
-       66.7 (32/48)       39.0 (16/41)       33.3 (3/9) 0.017 
   Bleeding symptoms (%) -       58.3 (28/48)       46.3 (19/41)       55.6 (5/9) 0.522 
Laboratory features (median, range)
   WBC count (/L) -      9120 (3,290–31,800)      8920 (440–49,050)      9100 (2,770–23,080) 0.941 
   Hgb (g/dL) -       7.90 (4.60–15.90)       8.70 (6.20–12.70)       8.40 (5.10–12.20) 0.050 
   PLT count (×109/L) -     13.00 (2.00–293.00)     42.00 (4.00–197.00)     52.00 (7.00–190.00) ＜0.001 
   Serum LDH (U/L) - 1697.00 (224–6,765) 1437.00 (413.00–7,955.00) 1332.00 (162.00–3,769.00) 0.728 
   Serum creatinine
 (mg/dL)
-       0.94 (0.35–7.15)       3.14 (0.52–19.50)       2.00 (0.68–19.5) ＜0.001
   Total bilirubin (mg/dL) -       3.20 (0.50–13.78)       1.44 (0.30–27.00)       1.10 (0.30–6.43) ＜0.001 
   ADAMTS-13 activity 
(＜10%)
-       0.00 (0.00–9.00)     77.00 (20.00–129.00)     83.00 (42.00–100.00) ＜0.001
   ADAMTS-13 inhibitor 
(AU/mL)
-       1.10 (0.00–5.80) - -
   PLASMIC score (IQR)            6 (5–7)            5 (4–5) 5 ＜0.001
Complement activation markers (median, range)
   C3a (ng/mL) 139.8 (31–473.8)     195.9 (62–404.4)     221.3 (80.7–791.8)     266.4 (115.7–483.8) 0.005
   C4d (ng/mL)    623 (31–3,871)        630 (1.8–5,803)     610.9 (0–4,221)        973 (22.6–2,492) 0.285
   C5a (ng/mL)   11.4 (2.7–69.1)       20.1 (2.7–68.6)       19.9 (5.4–66.1)       22.7 (8.7–37.4) 0.001
   C5b-9 (ng/mL)    155 (58–459)        292 (85–939)        317 (82–1,415)        340 (183–515) ＜0.001
   Factor Bb (ng/mL)    499 (110–2,072)        760 (1–16,557)     1,200 (270–11,797)     1,380 (52–2,490) ＜0.001
Treatment and prognosis
   Plasma exchange (%)       81.3 (39/48)       80.5 (33/41)       77.8 (7/9) 0.971
   Response rate (%) -       68.8 (33/48)       70.7 (29/41)       66.7 (6/9) 0.963 
   Remission rate (%) -       70.8 (34/48)       63.4 (26/41)       44.4 (4/9) 0.295 
   Relapse rate (%) -       12.5 (6/48)         4.9 (2/41)       11.1 (1/9) 0.453 
   Disease-associated
mortality (%)
-       18.8 (9/48)       24.4 (10/41)       11.1 (1/9) 0.619 
Bolded text signifies the values that were statistically significant at the P＜0.05 level.
Abbreviations: ADAMTS13, a disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13; aHUS, atypical hemolytic 
uremic syndrome; GC-aHUS, genetically confirmed aHUS; Hgb, hemoglobin; IQR, interquartile range; LDH, lactate dehydrogenase; PLT, 
platelet; TTP, thrombotic thrombocytopenic purpura; WBC, white blood cell.
let-poor plasma that were then frozen at -70oC. Complement 
activation products in aliquots were measured with ELISA 
for C3a (generalized pathway), factor Bb (alternative), C4d 
(classical and lectin), and C5b-9 (terminal) (Quidel, San 
Diego, CA, USA), as well as C5a (terminal) (BD, Franklin 
Lakes, NJ, USA). ADAMTS13 inhibitor levels were also de-
termined with ELISA (Sekisui Diagnostics, Stamford, CT, 
USA).
Definitions of TTP and aHUS
The diagnostic criteria for both conditions included micro-
angiopathic hemolytic anemia characterized by schistocytes 
in the peripheral blood smear and thrombocytopenia (platelet 
count ＜150,000/L), with TTP and aHUS differentiated by 
ADAMTS13 activity ＜10% and ＞10% (with no evidence 
of Shiga toxin-producing Escherichia coli or other known 
secondary TMA) [9, 10], respectively. The median value 
of ADAMTS13 activity levels among aHUS patients was 77%, 
and we defined the “high ADAMTS13 activity” as the levels 
higher than that. 
Clinical and hematological outcomes
Standardized report forms given 6 months after the blood 
tests were used to obtain clinical data regarding the PEX 
treatments and prognoses. The clinical outcomes were de-
fined according to the Oklahoma TTP-HUS registry [11]. 
It was defined as an improvement in the number of platelets, 
regardless of the renal function. A hematological response to 
PEX treatment was considered a platelet count ≥150,000/L 
(measured during or ≤1 week after treatment completion). 
Recurrent thrombocytopenia requiring re-administration of 
PEX treatment within 30 days was considered hematological 
exacerbation, whereas normal platelet counts during this 
time were considered hematological remission. A subsequent 
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Fig. 2. Summary box plots for the levels of complement activation products in healthy controls (N=40) and in patients with TTP (N=48), aHUS 
(N=41), or GC-aHUS (N=9) measured with ELISA. (A) C3a [ng/mL: control, 139.8 (31–473.8); TTP, 195.9 (62–404.4); aHUS, 221.3 (80.7–791.8); 
GC-aHUS, 266.4 (115.7–483.8); P=0.005]. (B) Factor Bb [ng/mL: control, 499 (110–2,072); TTP, 760 (1–16,557); aHUS, 1,200 (270–11,797); 
GC-aHUS, 1,380 (52–2490); P＜0.001]. (C) C5a [ng/mL: control, 11.4 (2.7–69.1); TTP, 20.1 (2.7–68.6); aHUS, 19.9 (5.4–66.1); GC-aHUS, 22.7 (8.7
–37.4); P=0.001]. (D) C5b-9 [ng/mL: control, 155 (58–459); TTP, 292 (85–939); aHUS, 317 (82–1,415); GC-aHUS, 340 (183–515); P＜0.001]. All 
the data represent the medians (ranges). The P -values were calculated using the Kruskal-Wallis test.
Abbreviations: aHUS, atypical hemolytic uremic syndrome; GC-aHUS, genetically confirmed aHUS; NS, not significant; TTP, thrombotic 
thrombocytopenic purpura. 
recurrence of TTP or aHUS after hematological remission 
was considered hematological relapse. Disease-associated 
mortality was assessed 30 days after the PEX treatment was 
completed.
aHUS genotyping
Genomic DNA from peripheral blood leukocytes was ex-
tracted with a G-DEX II kit (iNtRON Biotechnology, Korea) 
and used for sequencing and restriction fragment length 
polymorphism analyses for C3 and CFH mutations 
(Supplementary Table 1). To validate the results, analyses 
of each polymorphism were repeated for 30% of the PCRs 
(randomly selected) followed by DNA sequencing on an 
ABI 3730xl DNA analyzer (Applied Biosystems, Foster City, 
CA, USA). The quality control samples exhibited 100% 
concordance. For aHUS patients in whom polymorphisms 
were not detected, whole-exome sequencing was performed 
using an Agilent SureSelect All Exon 50 Mb Kit (Agilent 
Technologies) and the Illumina HiSeq 2500 platform. Five 
complement-related (C3, CFB, CFH, CFI, and CD46) and 
three coagulation-related (DGKE, PLG, and THBD) genes 
were screened. Rare variants (＜5%) were validated by 
Sanger sequencing. Multiplex ligation-dependent probe am-
plification was used to detect large gene deletions. The effects 
of missense variants on protein function and/or splice site 
were predicted with in silico analyses via Sorting Intolerant 
from Tolerant, Polymorphism Phenotyping v2, and/or 
Mutation Taster algorithms.
Statistical analysis
Patient groups were compared with Mann-Whitney U, 
Fisher’s exact, or 2 tests, where appropriate. Differences 
in complement activity were evaluated using a Kruskal- 
Wallis test. Data are reported as medians, ranges, and 25th–
75th percentiles. Multivariate logistic regression was per-
formed to assess the difference between hematological out-
comes and levels of complement activation markers including 
laboratory features, with odds ratios (ORs) and 95% con-
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Table 2. Correlations between the hematological outcomes and ADAMTS13 activity in patients with aHUS.
Hematological outcomes N %
High ADAMTS13 activity (N=25)
OR 95% CI P
No/subgroup (%)
Response 6.769 1.605–28.542 0.005 
   No 15 30   3/15 (20)
   Yes 35 70 22/35 (32.9)
Exacerbation 0.242 0.064–0.916 0.031 
   No 35 70 21/35 (60)
   Yes 15 30   4/15 (26.7)
Remission 6.000 1.693–21.262 0.004 
   No 20 40   5/20 (25)
   Yes 30 60 20/30 (66.7)
Relapse 2.087 0.177–24.615 1.000 
   No 47 94 23/47 (48.9)
   Yes 3 6   2/3 (66.7)
Disease-associated mortality 0.155 0.029–0.813 0.017 
   No 39 78 23/39 (59)
   Yes 11 22   2/11 (18.2)
High ADAMTS13 activity ≥77%. Bolded text signifies the values that were statistically significant at the P＜0.05 level. “Yes” or “no” indicates 
whether hematologic outcomes were present or absent.
Abbreviations: ADAMTS13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; CI, confidence interval; OR, 
odds ratio. 
fidence intervals (CIs) reported. P-values of ＜0.05 were 
considered statistically significant. Analyses were performed 
using SPSS version 20.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Patient characteristics
A total of 48 patients with TTP and 50 patients with 
aHUS [including genetically confirmed (GC)-aHUS] were 
enrolled in our study. Table 1 summarizes the baseline char-
acteristics of the study population. The age and sex dis-
tributions were similar among all the groups. The patients 
with TTP showed more predominant hematologic manifes-
tations than those with aHUS, such as lower platelet counts 
(median, 13,000 cells/L vs. 42,000 cells/L, respectively; 
P＜0.001) and hemoglobin levels (median, 7.9 g/dL vs. 8.7 
g/dL, respectively; P=0.05), and higher PLASMIC scores 
(median, 6 vs. 5, respectively; P＜0.001). In contrast, crea-
tinine levels reflecting acute kidney injury were higher in 
the patients with aHUS (median, 3.14 mg/dL vs. 0.94 mg/dL; 
P＜0.001). The disease groups were not different with respect 
to serum lactate dehydrogenase levels or clinical outcomes, 
such as response, remission, relapse, and disease-associated 
mortality. The median number of the PEX treatments was 
6.5 (range, 0–28) and 5 (range, 0–21) in the TTP and aHUS 
patients, respectively. The majority [44/48 (91.6%)] of the 
patients with TTP had inhibitors against ADAMTS13, and 
they all were newly diagnosed patients. Hemodialysis was 
performed in 34 of 50 (68.0%) aHUS patients and 9 of 48 
(18.8%) TTP patients. aHUS-related heterozygous mutations 
were identified in 9/50 (18%) patients with aHUS (i.e., CFH, 
1; CFB, 1; C3, 4; PLG, 2; THBD, 1) (Supplementary Table 
2). Complement biomarkers did not differ between the pa-
tients regardless of these identified mutations.
TTP is also associated with complement activation
The levels of each of the complement activation products 
were compared between TTP and aHUS patients (Fig. 2). 
Patients with aHUS had significantly higher levels of alter-
nate [C3a (P=0.005), C5a (P=0.001), and factor Bb (P＜0.001)] 
and terminal [C5b-9 (P＜0.001)] markers than those of the 
healthy controls. The levels did not differ between the two 
disease groups except for factor Bb, which was higher in 
the aHUS patients than in the TTP patients (median, 1,200 
ng/L vs. 760 ng/L, respectively; P=0.008). However, C4d 
levels did not significantly differ among the three groups 
(P=0.285). The results appeared the same in those of GC-aHUS.
Factors predictive of treatment outcomes according to 
ADAMTS13 activity
ADAMTS13 activity above normal (≥77%) was detected 
in 25 (50%) aHUS cases (Table 2). Above-normal ADAMTS13 
activity was significantly related to better outcomes, such 
as improved response (OR, 6.769; 95% CI, 1.605–28.542; 
P=0.005) and remission (OR, 6.000; 95% CI, 1.693–21.262; 
P=0.004) rates, and reduced rates of exacerbation (OR, 0.242; 
95% CI, 0.064–0.916; P=0.031) and disease-associated mortal-
ity (OR, 0.155; 95% CI, 0.029–0.813; P=0.017), but was not 
related to the relapse rate (OR, 2.087; 95% CI, 0.177–24.615; 
P＞0.05).
Table 3 summarizes the results of the multivariate re-
gression for treatment outcomes according to the levels of 
complement activation products. In patients with aHUS, a 
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Table 3. Multivariate association between laboratory features and hematological outcomes.
Hematological outcomes Variables
TTP (N=48) Total aHUS (N=50)
OR 95% CI P OR 95% CI P
Response C3a 0.998 0.989–1.007 0.668 1.002 0.994–1.010 0.655 
C4d 1.025 0.939–1.119 0.576 0.951 0.846–1.069 0.398 
C5a 1.018 0.953–1.087 0.602 1.048 0.961–1.143 0.289 
C5b-9 1.000 0.996–1.005 0.933 0.998 0.994–1.002 0.236 
Factor Bb 1.047 0.628–1.745 0.860 0.804 0.454–1.425 0.455 
Creatinine 0.848 0.529–1.361 0.495 1.433 1.001–2.051 0.049
Platelets 0.999 0.984–1.015 0.915 1.017 0.991–1.043 0.202
LDH 1.175 0.826–1.671 0.370 1.084 0.865–1.359 0.485 
ADAMTS13 1.005 0.771–1.310 0.969 1.050 1.009–1.093 0.016 
Exacerbation C3a 1.001 0.990–1.012 0.841 0.998 0.991–1.005 0.525 
C4d 1.067 0.960–1.185 0.228 1.005 0.910–1.110 0.924 
C5a 0.920 0.841–1.007 0.072 0.967 0.896–1.043 0.382 
C5b-9 1.003 0.997–1.009 0.349 1.002 0.999–1.006 0.232 
Factor Bb 0.733 0.279–1.927 0.529 1.186 0.698–2.014 0.528 
Creatinine 1.104 0.642–1.899 0.721 0.865 0.681–1.099 0.236
Platelets 1.006 0.989–1.024 0.492 0.988 0.967–1.010 0.300
LDH 1.031 0.685–1.552 0.883 0.943 0.773–1.151 0.564 
ADAMTS13 1.073 0.785–1.465 0.659 0.965 0.934–0.997 0.034 
Remission C3a 0.996 0.985–1.006 0.406 0.998 0.991–1.006 0.666 
C4d 0.996 0.907–1.093 0.928 0.968 0.880–1.065 0.503 
C5a 1.042 0.961–1.129 0.318 1.001 0.928–1.079 0.984 
C5b-9 0.999 0.994–1.005 0.823 0.999 0.995–1.003 0.586 
Factor Bb 0.798 0.514–1.238 0.314 0.688 0.368–1.285 0.241 
Creatinine 0.806 0.478–1.358 0.417 1.059 0.841–1.334 0.626
Platelets 1.001 0.985–1.018 0.862 1.036 1.006–1.065 0.016
LDH 1.544 1.005–2.334 0.059 1.176 0.966–1.432 0.105 
ADAMTS13 0.964 0.714–1.246 0.803 1.028 0.993–1.065 0.119 
Relapse C3a 0.996 0.977–1.014 0.648 1.003 0.988–1.019 0.659 
C4d 1.053 0.893–1.240 0.541 0.724 0.465–1.129 0.154
C5a 0.964 0.830–1.120 0.633 1.241 0.946–1.629 0.119 
C5b-9 1.004 0.996–1.012 0.344 0.996 0.986–1.006 0.404 
Factor Bb 0.638 0.197–2.066 0.453 0.463 0.059–3.622 0.463 
Creatinine 0.528 0.114–2.454 0.415 0.854 0.738–1.444 0.854
Platelets 0.851 0.625–1.159 0.305 0.732 0.960–1.029 0.732
LDH 1.822 0.875–3.791 0.109 0.635 0.509–1.510 0.635 
ADAMTS13 0.003 0.000 0.997 0.796 0.926–1.061 0.796 
Disease-associated mortality C3a 0.999 0.988–1.011 0.919 0.996 0.986–1.005 0.379 
C4d 0.978 0.850–1.126 0.759 1.077 0.951–1.219 0.242 
C5a 0.983 0.898–1.077 0.715 0.925 0.840–1.017 0.108 
C5b-9 1.001 0.996–1.007 0.633 1.003 0.999–1.007 0.147 
Factor Bb 0.904 0.488–1.674 0.748 1.452 0.797–2.648 0.223 
Creatinine 1.307 0.798–2.141 0.287 0.681 0.440–1.054 0.085
Platelets 1.003 0.986–1.020 0.762 0.988 0.962–1.014 0.368
LDH 0.819 0.506–1.323 0.414 1.010 0.816–1.250 0.926 
ADAMTS13 1.179 0.878–1.584 0.274 0.964 0.926–1.004 0.074 
Bolded text signifies the values that were statistically significant at the P＜0.05 level.
Abbreviations: ADAMTS13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; aHUS, atypical hemolytic 
uremic syndrome; CI, confidence interval; LDH, lactate dehydrogenase; OR, odds ratio; TTP, thrombotic thrombocytopenic purpura.
high level of ADAMTS13 activity was beneficial for hemato-
logic outcomes (response: OR, 1.050; 95% CI, 1.009–1.093; 
P=0.016; exacerbation: OR, 0.965; 95% CI, 0.934–0.997; 
P=0.034). In addition, serum creatinine (response: OR, 1.433; 
95% CI, 1.001–2.051; P=0.049) and platelet count (remission: 
OR, 1.036; 95% CI, 1.006–1.065; P=0.016) were related to 
better treatment outcomes. In those with TTP, none of the 
factors were statistically linked to hematologic outcomes. 
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DISCUSSION
The results of this study show that complement activation 
via the alternative rather than the classical or lectin pathway 
is increased in TTP and aHUS patients. Specifically, patients 
showed higher levels of generalized (C3a), alternate (factor 
Bb), and terminal (C5a and C5b-9) markers than healthy 
controls, whereas the levels of C4d were not different. These 
findings suggest that the classical or lectin pathway comple-
ment activation does not contribute to the pathophysiology 
of TTP and aHUS or differentiate between the two, unlike 
ADAMTS13 activity. In addition, abnormal complement ac-
tivation was not associated with poorer prognoses or adverse 
outcomes in TTP or aHUS patients.
Complement activation reflects the cooperativity among 
a variety of plasma proteins to fight invading microorganisms 
and maintain tissue homeostasis [12]. This activation involves 
three pathways, namely, classical, lectin, and alternative 
pathways, and is regulated by soluble factors, such as factors 
H and I, and thrombomodulin (encoded by THBD), and 
by membrane-bound regulators, including CD35, CD55, and 
CD59 as well as membrane cofactor protein (encoded by 
CD46) [13]. Dysregulated activation is the primary contrib-
utor to the pathogenesis of aHUS, and suppression via 
Eculizumab (anti-C5 monoclonal antibody) treatment is ef-
fective and safe [4, 13-15].
Relapse of TTP occurs in 20–30% of patients treated with 
PEX, and recurrence can be fatal [16]. Therefore, the identi-
fication of novel mechanisms contributing to TTP will lead 
to new potentially life-saving therapeutic modalities. The 
observed initial complement dysregulation in TTP might 
exacerbate organ damage or result from microcirculation 
thrombi causing tissue ischemia. Ruiz-Torres et al. [7] first 
reported on the complement activation in eight TMA 
patients. Reti et al. [17] confirmed that levels of C3a and 
C5b-9 are elevated in patients with TTP compared with 
those in healthy controls and are significantly decreased 
by treatment with PEX. Subsequently, Westwood et al. [18] 
demonstrated that complement activation product levels cor-
related with the levels of anti-ADAMTS13 IgG in TTP pa-
tients and PEX treatment significantly decreased the C3a 
levels. Recently Wu et al. [19] have found that patients 
with elevated levels of complement activation products had 
a poor prognosis and the levels were elevated in both TTP 
patients and aHUS patients. Recent results suggest that the 
ultra-large vWF multimer binds to complement and is in-
volved in the pathophysiology of the disease [20, 21]. This 
suggests that activation of the classical pathway is not a 
contributor to TTP or aHUS, which is supported by our 
findings.
Cataland et al. [9] suggested that complement activation 
biomarkers may be useful to differentiate TTP from aHUS. 
However, our data showed that the levels of generalized 
(C3a) and terminal (C5a and C5b-9) markers of complement 
activation were similar in both diseases, and although the 
median level of factor Bb was higher in the group of aHUS 
patients, there was a substantial overlap in levels between 
the patients with TTP and those with aHUS. The discrep-
ancies between these studies may be due to the differences 
in the study subjects or a wide variation in the normal range 
of the complement activation product levels. The response 
rates to PEX treatment were also remarkably different (70% 
in our study vs. 38% reported by Cataland et al.) [9]. Thus, 
the severity of the disease in the patients in the two studies 
may also be different. Another possible explanation is that 
similar levels of complement activation may be induced by 
sepsis or other nonspecific complications of both TTP and 
aHUS. However, it may be difficult to distinguish between 
TTP and aHUS by assessing complement activation early 
in the disease progression at initial presentation, whereas 
since the activation is sustained in aHUS patients, it is easier 
to distinguish the two diseases at later stages. The activation 
may be transient in TTP, as PEX treatment remedies the 
ultra-large VWF, thereby reducing complement binding [17, 
18, 22]. Serial measurement during remission or after the 
initial treatment may be a more rational approach to evaluate 
the status of complement activation and to differentiate TTP 
from aHUS.
A severe deficiency of ADAMTS13 activity (＜10%) is 
diagnostic for TTP, and the prolonged decrease in activity 
is related to poor prognosis and recurrence [16]. Moreover, 
decreases in ADAMTS13 activity and associated poor prog-
noses have been reported for other diseases, including during 
severe sepsis [23], malignant and autoimmune diseases, trans-
plantation of solid organs [24], and malignant hypertension 
[25]. Although deficient ADAMTS13 activity does not con-
tribute to the development of TMAs other than TTP, it 
has an important prognostic role. We here show that elevated 
ADAMTS13 activity predicts favorable clinical outcomes for 
patients with aHUS treated by PEX. The cause of the low 
ADAMTS13 activity is unknown, but perhaps, it reflects 
the complement-mediated binding and clearance of 
ADAMTS13 by VWF. Therefore, the results of our study 
suggest that ADAMTS13 activity can be used to determine 
the appropriate treatment options for aHUS patients as a 
result of differentiation from TTP patients, in addition to 
serving as a prognostic indicator to determine whether addi-
tional therapies, such as Eculizumab, should be administered.
Because of the high mortality associated with TTP, rapid 
diagnosis and timely treatment are crucial. Researchers at 
Massachusetts General Hospital recently developed the 
PLASMIC score as a diagnostic tool [26]. When comparing 
patients with high risk (score of 6 or 7) and those with 
low or intermediate risk (score of ≤5), our model predicted 
severe ADAMTS13 deficiency with a positive predictive val-
ue of 76%, negative predictive value of 75%, sensitivity of 
73%, and specificity of 78% (Supplementary Table 3). Thus, 
the PLASMIC score is not sufficient to distinguish TTP from 
other TMAs, and ADAMTS13 activity in patients should 
be measured as soon as possible.
The results presented here are based on a retrospective 
multicenter analysis, which was limited by the relatively 
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small number of patients. Nevertheless, TTP and aHUS are 
rare diseases, and obtaining larger population sizes may be 
challenging. Furthermore, differences in blood collection 
and processing among centers may result in sampling bias; 
however, the risk of bias is low, because these institutes 
have participated in a wide variety of studies with stand-
ardized blood samples. Of note, the blood samples used for 
the analyses in this study were collected before the start 
of PEX treatment. Further research involving repeated blood 
collection during and after the treatment is needed. Only 
18% of the aHUS patients were found to have genetic muta-
tions in our study, whereas approximately 50% of the patients 
in the previous studies were found to carry the genetic 
alterations. It seems likely that the main reason for this 
gap is due to the ethnic differences because other possible 
factors, such as Shiga-toxin–producing infection, pregnancy, 
chemotherapy, sepsis, or other clear causes of TMA were 
thoroughly excluded in our study. Given that only 21.6% 
of the genetic mutations were detected in the studies on 
pediatric aHUS patients in Korea [27], ethnic difference is 
one possible explanation for this gap. Further studies with 
a larger cohort of patients need to be undertaken to support 
this possibility.
In summary, the data presented here indicate that the 
levels of complement activation biomarkers (except factor 
Bb) are similar among newly diagnosed TTP and aHUS 
patients. The level of ADAMTS13 activity may be useful 
not only for diagnosing TTP but also for predicting the clin-
ical outcomes of the aHUS patients under PEX treatment. 
To the best of our knowledge, this is the first report linking 
high normal ADAMTS13 activity with improved outcomes 
of PEX treatments in aHUS patients. Given that a specific 
therapy exists for the treatment of aHUS, better diagnostic 
and prognostic tools for early recognition are necessary to 
improve patient outcomes These measures may distinguish 
patients requiring more intensive management, and the re-
sults presented here lay the groundwork for future multi-
center studies aimed at identifying prognostic markers for 
aHUS and TMA.
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APPENDIX
List of The Korean TTP Registry investigators and affiliations:
Y. Park (Department of Internal Medicine, Korea University 
College of Medicine), H. Kim (Department of Internal 
Medicine, University of Ulsan College of Medicine), H. G. 
Lee (Department of Internal Medicine, Konkuk University
School of Medicine), J. S. Kim (Department of Internal 
Medicine, Yonsei University College of Medicine), J. Hong 
(Department of Internal Medicine, Gachon University of 
Medicine and Science Graduate School of Medicine), W. 
S. Lee (Department of Internal Medicine, In Je University 
College of Medicine) Y. O. Kim and J.W. Lee (Department 
of Internal Medicine, Catholic University College of 
Medicine), I. H. Kim and S. M. Bang (Department of Internal 
Medicine, Seoul National University College of Medicine), 
C. W. Jung (Department of Internal Medicine, 
Sungkyunkwan University School of Medicine), H. J. Shin 
(Department of Internal Medicine, Pusan National 
University College of Medicine), Y. K. Kim (Department 
of Internal Medicine, Chonnam National University College 
of Medicine), D. Y. Jo (Department of Internal Medicine, 
Chungnam National University College of Medicine), H. J. 
Yoon (Department of Internal Medicine, Kyunghee 
University College of Medicine), H. Y. Yhim (Department 
of Internal Medicine, Jeonbuk National University Medical 
School), and S. K. Sohn (Department of Internal Medicine, 
Kyungpook National University College of Medicine), K. 
W. Lee (Department of Internal Medicine, Gyeongsang 
National University College of Medicine), S. H. Han 
(Department of Internal Medicine, Jeju National University 
College of Medicine).
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Supplementary Table 1. Restriction fragment length polymorphism procedures for C3 and CFH mutation analysis.
Gene name Target mutation Primer sequence Restriction enzyme PCR product size (bp)
C3 p.R425C F: 5ʹ- CAA TTC CCA GGT CTC AGG GA - 3ʹ
R: 5ʹ- GAG AGA AAA GGA GAA AGG G - 3ʹ
Hha I Wild type : 493+250 
Mutated : 493+170+80
C3 p.S562L F: 5ʹ- CAA TTC CCA GGT CTC AGG GA - 3ʹ
R: 5ʹ- GAG AGA AAA GGA GAA AGG G - 3ʹ
Ban II Wild type : 229+175+102 
Mutated : 229+155+102 
CFH p.Y355S F: 5ʹ- GCA AGT GAA ACC TTG TGA TTA TCC -3ʹ
R: 5ʹ- GGT GTA ATC ACT TAT GTG CTC TCC -3ʹ
BseR I Wild type : 281 
Mutated : 168+113
CFH p.C926F F: 5ʹ- TGT TCA CAA CCA CCT CAG A -3
R: 5ʹ- TGC CAG AAT ACA AAG TGA CTC -3ʹ
Ale I Wild type : 382
Mutated : 217+165
CFH p.C1077W F: 5ʹ- AAT GAA CAC TAG GTG GAA CCA -3ʹ
R: 5ʹ- TCT ACC TTT GCA TTG AGG TGG -3ʹ
BseR I Wild type : 223
Mutated : 152+71
CFH p.Q1139X F: 5ʹ- CTG TGT TTG CGT TTG CCT TA -3ʹ
R: 5ʹ'- CAC CCA GCC CTA AAG AGA AA -3ʹ
Bfa I Wild type : 437
Mutated : 251+186
CFH p.R1215G F: 5ʹ- ATC CGT GTG TAA TAT CCC GAG A - 3ʹ
R: 5ʹ- GCA CAA GTT GGA ATC TCC AGT - 3ʹ
BsrD I Wild type : 144+49
Mutated : 193
Abbreviation: C3, complement 3 CFH complement factor H.
Supplementary Table 3. Correlation between the PLASMIC score and ADAMTS13 activity.
PLASMIC score N (%)
ADAMTS13 activity
OR 95% CI P
≤10% (N=48) ＞10% (N=50)
6 or 7 46 (47) 35 11
9.545 3.791–24.038 ＜0.001
≤5 52 (53) 13 39
Value (%) 95% CI
Sensitivity 73 0.579–0.843
Specificity 78 0.637–0.880
Positive predictive value 76 0.609–0.869
Negative predictive value 75 0.608–0.855
Abbreviations: ADAMTS13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; CI, confidence interval; OR, 
odds ratio. 
Supplementary Table 2. Characteristics of aHUS patients with genetic abnormalities.









CFH c.3572C＞T, p.Ser1191Leu 53 F 91   8.4 14   1.58 2,146 Alive
C3 c.1273C＞T, p.Arg425Cys 23 F 91 10.6 98   0.68 602 Alive
C3 c.1273C＞T, p.Arg425Cys 88 F 42 12.2 91   2 369 Dead at HD 11
C3 c.1273C＞T, p.Arg425Cys 66 F 83 11.2 19   1.25 1,192 Alive
C3 c.1685C＞T, p.Ser562Leu 64 F 61   8.2 7   1.4 3,769 Alive
Plasminogen c.1858G＞A, p.Ala620Thr 56 F 67   9 52   4.1 1,332 Dead at HD 117
Plasminogen c.1858G＞A, p.Ala620Thr 27 M 27   7.8 25 11.93 162 Recurrence
THBD c.1456G＞T p.Asp486Tyr 31 M 31   7.8 92 19.5 2,445 Alive
CFB c.1598A＞G p.Lys533Arg 33 F 94   5.1 10   2.64 2,302 Alive
Abbreviations: ADAMTS13, a disintegrin and metalloprotease with a thrombospondin type 1 motif, member 13; aHUS, atypical hemolytic 
uremic syndrome; C3, complement 3; CFB, complement factor B; CFH, complement factor H; Cr., serum creatinine; HD, hospital day; Hgb, 
hemoglobin; LDH, lactate dehydrogenase; PLT, platelet; THBD, thrombomodulin. 
